Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | FCER2 | P06734 | 4/20 | 0.53 |
| ▸ | MMP1 | P03956 | 2/20 | 0.53 |
| ▸ | HPGDS | O60760 | 3/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | MMP14 | P50281 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19584939 | 0.87 | MMP9 (0.56) | FCER2MMP1HPGDSMMP9MMP8 | |
| SCHEMBL3107407 | 0.84 | FCER2 (0.52) | LTA4HFCER2MMP1HPGDSMMP9 | |
| SCHEMBL14269021 | 0.84 | FCER2 (0.62) | FCER2MMP1ACE | |
| SCHEMBL15851264 | 0.84 | FCER2 (0.62) | FCER2MMP1ACE | |
| SCHEMBL15851263 | 0.84 | FCER2 (0.62) | FCER2MMP1ACE | |
| SCHEMBL8374049 | 0.82 | FCER2 (0.50) | LTA4HFCER2MMP1HPGDSMMP9 | |
| SCHEMBL3105957 | 0.82 | CA12 (0.55) | LTA4HFCER2MMP1HPGDSMMP9 | |
| SCHEMBL15810862 | 0.81 | CTSS (0.61) | FCER2MMP1HPGDS | |
| SCHEMBL1431724 | 0.81 | FCER2 (0.51) | LTA4HFCER2MMP1HPGDSNPC1 | |
| SCHEMBL13707917 | 0.81 | FCER2 (0.51) | LTA4HFCER2MMP1HPGDSNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732605-B2 | Synthesis of diketopiperazines | NEREUS PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732605-B2 | Synthesis of diketopiperazines | NEREUS PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732605-B2 | Synthesis of diketopiperazines | NEREUS PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20060235226-A1 | Synthesis of diketopiperazines | BEYONDSPRING PHARMACEUTICALS, INC. | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235226-A1 | Synthesis of diketopiperazines | DHPS, COASY, TKT | LTA4H 2059/4885FCER2 4479/4885MMP1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.